Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
4K televisions for Extreme Film Watching Experience- Best Getaway destination: Ocean side, Mountain, or City
- Gauging the Upsides and downsides of Visas: A Complete Aide
- Step by step instructions to Buy a Jeep Wrangler on a Senior's Spending plan
- NASA probe captures stunning photos of Earth and moon on the way to infamous asteroid Apophis
- 5 Language Learning Applications
- Consume Fat Quick: 10 Demonstrated Activities for Ideal Outcomes
- 2026 Golden Globes: How to watch, start time, TV channel, full nominee list and more
- 3 astronauts settle into their new life in orbit | On the International Space Station this week Dec. 1-5, 2025
